Clinical trials: Cancer Patient
Aggressive Systemic Mastocytosis (ASM), SM w Assoc Clonal Hema Non-mast Cell Lineage Disease (SM-AHNMD)
Patient-Reported Outcome Questionnaire for Systemic Mastocytosis
The purpose of this study is to explore the key symptoms of individuals with systemic mastocytosis. Interviews of enrolled individuals will be conducted to learn about the disease symptoms and condition.
- Conditions
- Aggressive Systemic Mastocytosis (ASM), SM w Assoc Clonal Hema Non-mast Cell Lineage Disease (SM-AHNMD), Mast Cell Leukemia (MCL), Smoldering Systemic Mastocytosis (SSM)
- Trial name
- NCT02380222
- Testing
- Interview
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Adelphi Values LLC
Intraductal Papillary Mucinous Neoplasm
Intra-operative Pancreatoscopy in Patients With IPMN
To demonstrate the added value of intraoperative pancreatoscopy in patients undergoing partial pancreatic resection for the treatment of Intraductal Papillary Mucinous Neoplasm (IPMN) as it pertains to detection of discontinuous…
- Trial name
- NCT03729453
- Testing
- SpyGlass
- Where
- 8 sites in United States, China and 4 more
- Volunteers
- 100 people
- Sponsor
- Boston Scientific Corporation
Previously Treated CD20+ B-cell Malignancies
Phase I Study of Subcutaneous Ocaratuzumab in Patients With Previously Treated CD20+ B-Cell Malignancies
Ocaratuzumab is a third-generation, fully humanized IgG1 monoclonal antibody (mAb) targeting the CD20 surface marker on normal and malignant B lymphocytes.
- Trial name
- NCT01858181
- Testing
- ocaratuzumab
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Mentrik Biotech, LLC
Breast Cancer, Gastric Cancer
Trial of KN026 in Patients With HER2-positive Advanced Malignant Breast Cancer and Gastric Cancer
This is a first-in-human (FIH), open-label, phase 1 dose-escalation study of KN026 in subjects with HER2 positive advanced breast and Gastric Cancer. The standard "3 + 3" design was used for dose escalation.
- Trial name
- NCT03619681
- Testing
- KN026
- Where
- China
- Volunteers
- 63 people
- Sponsor
- Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Melanoma
X4P-001 and Pembrolizumab in Patients With Advanced Melanoma
The goals of this protocol are 1) to investigate the safety and tolerability of X4P-001 in combination with Keytruda® (pembrolizumab) in patients with advanced melanoma, and 2) to assess serial biopsies of melanoma tumor lesions…
- Trial name
- X4P-001-MELA (NCT02823405)
- Testing
- X4P-001, Pembrolizumab
- Where
- 4 sites in United States
- Volunteers
- 16 people
- Sponsor
- X4 Pharmaceuticals
Gastro-intestinal Stromal Tumours
Masitinib in Locally Advanced/Metastatic Gastro-intestinal Stromal Tumour (GIST)
The objective is to evaluate the efficacy and safety of AB1010 at 7.5 mg/kg/day in the treatment of non pre-treated, inoperable patients with locally advanced/metastatic GIST.
- Trial name
- NCT00998751
- Testing
- oral masitinib
- Where
- France
- Volunteers
- 30 people
- Sponsor
- AB Science
Breast Cancer
A Study of ABT-751 in Patients With Recurrent Breast Cancer After Taxane (Taxol or Taxotere) Therapy.
The purpose of the study is to determine if ABT-751 will decrease tumors, and determine how long the tumor shrinkage can be maintained in patients with breast cancer after having had taxol or taxotere.
- Trial name
- NCT00063102
- Testing
- ABT-751
- Where
- 8 sites in United States
- Volunteers
- 40 people
- Sponsor
- Abbott
Advanced Solid Tumors
A Phase I, Open-Label, Multicentre Study to Evaluate the Safety, Tolerability and Pharmacokinetics of MEDI4736 in Patients With Advanced Solid Tumours
This is a phase I, open-label, multicentre study of MEDI4736 administered intravenously with a standard 3+3 dose-escalation phase to evaluate safety, tolerability, and pharmacokinetics in patients with advanced solid tumor…
- Trial name
- NCT01938612
- Testing
- MEDI4736, tremelimumab
- Where
- 21 sites in Japan, South Korea and 1 more
- Volunteers
- 269 people
- Sponsor
- AstraZeneca
HER2 Positive Breast Cancers
A Study of Tucatinib (ONT-380) Combined With Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2+ Breast Cancer
The purpose of this study is to determine the maximal tolerated dose (MTD) or recommended dose (RD) and to assess the safety and tolerability of tucatinib (ONT-380) combined with ado-trastuzumab emtansine (T-DM1) in patients with…
- Trial name
- NCT01983501
- Testing
- Tucatinib (ONT-380), T-DM1
- Where
- 11 sites in United States, Canada
- Volunteers
- 57 people
- Sponsor
- Seagen Inc.
Advanced Solid Tumors
Phase I Dose-Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of BVD-523 in Patients With Advanced Malignancies
This open-label, multi-center Phase 1/2 study will assess the safety, pharmacokinetics, and pharmacodynamics of escalating doses of BVD-523 in patients with advanced malignancies.
- Trial name
- NCT01781429
- Testing
- BVD-523
- Where
- 9 sites in United States
- Volunteers
- 136 people
- Sponsor
- BioMed Valley Discoveries, Inc
Non-Small Cell Lung Cancer
A Study of Tarceva (Erlotinib) in Sequential Combination With Gemcitabine as First Line Therapy in Patients With Advanced Non-Small Cell Lung Cancer
This 2 arm study will compare the efficacy and safety of sequential treatment with Tarceva and gemcitabine, and of gemcitabine monotherapy, as first line treatment of elderly patients, or patients with ECOG performance status of…
- Trial name
- NCT00940875
- Testing
- erlotinib [Tarceva], gemcitabine
- Where
- 17 sites in Australia
- Volunteers
- 54 people
- Sponsor
- Hoffmann-La Roche
PCOS (Polycystic Ovary Syndrome) of Bilateral Ovaries
Letrozole Alone Protocol Versus Using Letrozole and HCG Protocol
Letrozole is a chemical compound, CGS 20267 which is a third-generation, nonsteroidal aromatase inhibitor. Letrozole blocks estrogen synthesis by directly affecting the hypothalamic-pituitary-ovarian axis, subsequently, increases…
- Trial name
- NCT06367712
- Testing
- Letrozole tablets
- Where
- Egypt
- Volunteers
- 132 people
- Sponsor
- Egymedicalpedia
Giant Cell Tumors
Tenosynovial Giant Cell Tumors (TGCT) Observational Platform Project
TGCT is a rare disease that is difficult to manage, surgical resection is the primary treatment currently available. To date no disease registry exists and there is little data available detailing the management of patients with…
- Trial name
- TOP (NCT02948088)
- Where
- 15 sites in United States, Austria and 6 more
- Volunteers
- 183 people
- Sponsor
- Daiichi Sankyo
Prostate Cancer
Pharmacogenomics IND Commercial SNP Clinical Study - Abiraterone and Single Nucleotide Polymorphisms
The usual approach group, 300 double blind random group separated PC patients currently used the Combined Chemotherapy on ZYTIGA - abiraterone acetate tablet, film coated plus prednisone tablet plus BICALUTAMIDE tablet, it will…
- Trial name
- Drugs-SNPs (NCT03348670)
- Testing
- Abiraterone - Usual, Abiraterone - Study
- Where
- United States
- Volunteers
- 600 people
- Sponsor
- Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair
Multiple Myeloma
Peginterferon α-2b as a Maintenance Therapy in Participants With Multiple Myeloma Who Responded to Induction Therapy (P01972-AM7)
This study aims to assess the efficacy of peginterferon α-2b, compared to a control arm not receiving any maintenance treatment, in adult subjects with multiple myeloma who have responded to a prior induction therapy.
- Trial name
- NCT00732641
- Testing
- Peginterferon
- Volunteers
- 244 people
- Sponsor
- Merck Sharp & Dohme LLC
Non-small Cell Lung Cancer
Phase III Study of Envafolimab Versus Placebo Plus Chemotherapy in Resectable Stage III NSCLC
This is a randomized, controlled, double-blind, multicenter Phase 3 clinical study to assess the efficacy and safety of envafolimab plus platinum-based doublet chemotherapy versus placebo plus platinum-based doublet chemotherapy…
- Trial name
- NCT06123754
- Testing
- Envalfolimab subcutaneously injected+Platinum-based doublet chemotherapy intravenous injection
- Where
- China
- Volunteers
- 390 people
- Sponsor
- 3D Medicines (Sichuan) Co., Ltd.
Multiple Myeloma
Japanese Phase 1 Study to Evaluate Tolerated Dose, Safety, and Efficacy of Pomalidomide in Patients With Refractory or Relapsed and Refractory Multiple Myeloma
The purpose of this study is to determine the tolerated dose of pomalidomide and also to evaluate the pharmacokinetics, safety and efficacy of pomalidomide in patients with refractory or relapsed and refractory multiple myeloma.
- Trial name
- NCT01568294
- Testing
- pomalidomide
- Where
- 8 sites in Japan
- Volunteers
- 12 people
- Sponsor
- Celgene
Non-Small Cell Lung Cancer
A Study of the Combination of Erlotinib and Pertuzumab in Patients With Relapsed Non-small Cell Lung Cancer
This was a Phase II, open-label, single-arm, single-stage, multicenter trial in patients with relapsed non-small cell lung cancer (NSCLC), with the objective of assessing the activity of the combination of erlotinib and…
- Trial name
- PENGUIN (NCT00855894)
- Testing
- Pertuzumab, Erlotinib
- Where
- 10 sites in United States, Australia
- Volunteers
- 41 people
- Sponsor
- Genentech, Inc.
Acute Myeloid Leukemia
Study to Assess the Safety and Tolerability of AZD1152 in Combination With Low Dose Cytosine Arabinoside (LDAC)
A study to assess the safety and tolerability of AZD1152 in combination with low dose cytosine arabinoside (LDAC) in patients with acute myeloid leukaemia (AML).
- Trial name
- NCT00926731
- Testing
- AZD1152, LDAC (low dose cytosine arabinoside)
- Where
- 4 sites in United States, France
- Volunteers
- 4 people
- Sponsor
- AstraZeneca
Head Cancer Neck
Evaluation of Oncoxin-Viusid® in Head and Neck Cancer
Nutritional supplements containing antioxidants seem to decrease toxicity associated with Radiotherapy (RT) and Chemotherapy (CT) in patients with malignant head and neck tumors.
- Trial name
- NCT03541772
- Testing
- Oncoxin-Viusid®
- Where
- Cuba
- Volunteers
- 60 people
- Sponsor
- Catalysis SL
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.